1. Technical Field
The present disclosure relates to electrosurgical systems and devices for performing medical procedures. The present disclosure relates to the administration of beneficial agents in general, which include any physiologically, pharmacologically active and/or psychotropic substance(s). More particularly, the present disclosure relates to a drug-delivery cannula assembly suitable for use with medical devices, such as for example, electrosurgical devices, and electrosurgical systems including the same.
2. Discussion of Related Art
Surgical techniques and instruments have been developed that allow the surgeon to perform an increasing range of surgical procedures with minimal incisions into the skin and body tissue of the patient. Minimally invasive surgery has become widely accepted in many medical specialties, often replacing traditional open surgery. Minimally invasive surgical procedures where trocar assemblies are desirable or even necessary are continually increasing in number and variety.
Minimally-invasive surgical procedures are performed throughout the body and generally rely on obtaining access to an internal surgical site through a relatively small pathway, often less than one centimeter in diameter, to the surgical site. One method of providing such a pathway is by inserting a cannula and trocar assembly through the skin of the patient. Commonly, to place the trocar-cannula, the penetrating tip of the obturator of the trocar is pushed through the skin and underlying tissue until the distal end of the cannula is within the body cavity. Alternatively, some trocar devices have a blunt obturator for placing the cannula through a previously-made incision. Once the trocar has been properly positioned, the obturator is removed and the cannula is then available as a pathway between the surgical site and the exterior of the patient's body through which the surgeon may introduce the various surgical instruments required to perform the desired procedures. Surgical instruments insertable through a cannula include forceps, clamps, scissors, probes, flexible or rigid scopes, staplers and cutting instruments.
The term “trocar” originally referred to a pointed device for penetrating body tissues having a three-faceted pyramidal point. Commonly, a trocar includes an obturator assembly including a shaft having a proximal end connected to a hand grip and a sharpened, pyramidal or conical tip at the distal end of the shaft for penetrating body tissue. Trocars may have their obturators secured to the hand grip so that the obturator cannot rotate separately from the hand grip. Some obturators include a tip portion that is detachable and disposable.
“Trocar” is a term now widely used to describe surgical instruments for placing an access cannula into a body cavity for endoscopic surgery, including laparoscopy, arthroscopy and thoracoscopy. This type of trocar device includes a trocar cannula, also referred to as a trocar tube or sleeve, with an obturator assembly removeably inserted through the lumen of the cannula for penetrating the body tissue.
Trocar assemblies are typically made of metal to facilitate sterilization and re-use. Medical grade stainless steel and titanium metal are commonly used.
Treatment of certain diseases requires the destruction of malignant tissue growths, e.g., tumors. Electromagnetic radiation can be used to heat and destroy tumor cells. Treatment may involve inserting ablation probes into tissues where cancerous tumors have been identified. Once the probes are positioned, electromagnetic energy is passed through the probes into surrounding tissue.
Electrosurgical devices utilizing electromagnetic radiation have been developed for a variety of uses and applications. A number of devices are available that can be used to provide high bursts of energy for short periods of time to achieve cutting and coagulative effects on various tissues. There are a number of different types of apparatus that can be used to perform ablation procedures. Typically, microwave apparatus for use in ablation procedures include a microwave generator that functions as an energy source, and a microwave surgical instrument (e.g., microwave ablation probe) having an antenna assembly for directing the energy to the target tissue. The microwave generator and surgical instrument are typically operatively coupled by a cable assembly having a plurality of conductors for transmitting microwave energy from the generator to the instrument, and for communicating control, feedback and identification signals between the instrument and the generator.
The benefits provided by controlled delivery of active agents for the treatment of injury or disease are well recognized in the art and various approaches have been taken to realize the goal of delivering active agents at desired rates over predetermined periods of time. Various different implantable controlled delivery formulations are known in the art, and various different mechanisms have been employed for delivering an active agent from implantable formulations at a controlled rate over time.
Medical imaging has become a significant component in the clinical setting and in basic physiology and biology research, e.g., due to enhanced spatial resolution, accuracy and contrast mechanisms that have been made widely available. Medical imaging now incorporates a wide variety of modalities, e.g., computed tomography (CT) and magnetic resonance imaging (MRI), which noninvasively capture the structure and/or function of the human body. Such images are acquired and used in many different ways including medical images for diagnosis, staging and therapeutic management of malignant disease.
Medical image processing, analysis and visualization play an increasingly useful role in disease diagnosis and monitoring as well as, among other things, surgical planning and monitoring of therapeutic procedures. A contrast agent may be used for enhancement of the contrast of structures or fluids within the body (or region of interest) in medical imaging to allow visualization and evaluation of lesions seen minimally, if at all, with imaging alone. There is a continuing need for devices capable of dispensing a contrast agent to enhance the visualization of the lesion during a surgical procedure.
Despite advancements in the use of electrosurgical devices for treating biological tissue, there are still concerns for tumor reoccurrence. A further continuing need exists for devices capable of dispensing a controlled delivery formulation of a desired active agent, which may help reduce or eliminate tumor reoccurrence.
There is a need for drug-delivery devices suitable for use with surgical instruments, e.g., ablation devices, to provide the capability of dispensing a controlled delivery formulation of a desired active agent (and/or contrast agent). The combination of ablation (e.g., RF ablation and/or microwave ablation) and drug delivery may help to reduce or eliminate tumor reoccurrence. The combination of ablation and contrast agent introduction may help to enhance the visualization of the lesion during the treatment procedure. There is a need for drug-delivery devices configured for use with ablation devices to provide the capability of dispensing an active agent in a controlled delivery formulation and/or non-active agent (e.g., contrast agent) before, during and/or after ablation, e.g., without the need for further manipulation of the device.
As it is used in this description, “ablation procedure” generally refers to any ablation procedure, such as, for example, microwave ablation, radio frequency (RF) ablation or microwave ablation-assisted resection. As it is used in this description, “energy-delivery device” generally refers to any device that can be used to transfer energy from a power generating source, such as a microwave or RF electrosurgical generator, to tissue. For the purposes herein, the term “ablation device” is interchangeable with the term “energy-delivery device.” As it is used in this description, “transmission line” generally refers to any transmission medium that can be used for the propagation of signals from one point to another.
As it is used in this description, “trocar” generally includes sharp-pointed surgical instruments used to penetrate body tissue, although the instruments may not have a three-faced pyramidal tip from which the term “trocar” is derived. As it is used in this description, “frusto-conical” refers to a geometric form based on a cone of which the apex has been “cut off” by a plane parallel to its base.
For the purposes of this description, the terms “drug,” “drug agent,” “implantable drug agent,” “active agent,” “beneficial agent,” “therapeutic agent,” “therapeutic molecule,” and the like are used interchangeably herein, and may include, for example, small molecules, proteins, enzymes, hormones, polynucleotides, nucleoproteins, polysaccharides, glycoproteins, lipoproteins, polypeptides, steroids, analgesics, local anesthetics, antibiotic agents, anti-inflammatory corticosteroids, ocular drugs and synthetic analogs of these species. Some examples of drug agents that may be delivered by devices according to embodiments of the present disclosure are provided later in this description.
According to an aspect of the present disclosure, a drug-delivery device is provided. The drug-delivery cannula assembly includes a cannula housing adapted for receiving one or more obturator shafts of an obturator assembly therethrough, one or more cannulae, and a supply line coupled to the cannula housing. The one or more cannulae define a longitudinal axis and a passageway aligned with the longitudinal axis. The one or more cannulae each include a proximal end coupled to the cannula housing. The cannula housing is configured to fluidly-couple the one or more cannulae to a source of a drug delivery supply for supplying drugs via the supply line to the one or more cannulae.
According to an aspect of the present disclosure, a drug-delivery device is provided. The drug-delivery cannula assembly includes a cannula housing adapted for receiving one or more ablation probes of an ablation device therethrough, one or more cannulae, and a supply line coupled to the cannula housing. The one or more cannulae define a longitudinal axis and a passageway aligned with the longitudinal axis. The one or more cannulae each include a proximal end coupled to the cannula housing. The cannula housing is configured to fluidly-couple the one or more cannulae to a source of a drug delivery supply for supplying drugs via the supply line to the one or more cannulae.
Objects and features of the presently-disclosed drug-delivery cannula assemblies suitable for use with electrosurgical devices, e.g., ablation devices, and electrosurgical systems including the same will become apparent to those of ordinary skill in the art when descriptions of various embodiments thereof are read with reference to the accompanying drawings, of which:
Hereinafter, embodiments of the presently-disclosed drug-delivery cannula assembly suitable for use with electrosurgical devices, e.g., ablation devices, and electrosurgical systems including the same are described with reference to the accompanying drawings. Like reference numerals may refer to similar or identical elements throughout the description of the figures. As shown in the drawings and as used in this description, and as is traditional when referring to relative positioning on an object, the term “proximal” refers to that portion of the apparatus that is closer to the user and the term “distal” refers to that portion of the apparatus that is farther from the user.
The principles of the present disclosure are applicable to a variety of surgical devices adapted for providing access to a surgical site within a patient's body. These devices include trocar assemblies, access cannulae, catheters, scopes, etc. The presently-disclosed drug-delivery cannula assemblies are contemplated for use in various surgical procedures, e.g., minimally invasive procedures or open surgical procedures. Portions of the presently disclosed drug-delivery cannula assemblies may be disposable, replaceable and/or reusable.
Obturator assembly 15 is adapted to cooperate with the drug-delivery cannula assembly 10. Obturator assembly 15 includes a hand grip 2 configured to be grasped by the user, three obturator shafts 6 connected to the hand grip 2 and having a distal end, which may include a sharpened tip portion. In some embodiments, as shown in
Hand grip 2 is generally configured to be grasped by the user, and may be provided with a cushioned, slip-resistant member. A cushioned member (not shown) may be formed from a thermoplastic elastomer, e.g., Versaflex™ or Santaprene™, and over-molded onto the hand grip 2 of the obturator assembly 15. Alternatively, a cushioned member may be formed of other cushioned or pliant materials, e.g., elastomeric or synthetic materials, including isoprenes, nitrile or silicon containing material, etc. The cushioned member may be fastened to the hand grip 2 using any suitable fastening techniques, e.g., physical, chemical or mechanical, including adhesives, welding, screws, etc. The shape and size of the hand grip 2 may be varied from the configuration depicted in
In some embodiments, a lower portion 24 of the hand grip 2 of the obturator assembly 15 may be configured for mating engagement with an upper portion 36 (
Each of the cannulae 12 defines a longitudinal axis “A-A” (
In some embodiments, the cannulae 12 may include a converging or frusto-conical section extending from the upper end 16. Cannula housing 31 may be adapted to releaseably engage an outer surface of the converging or frusto-conical section. Additionally, or alternatively, the hand grip 2 of the obturator assembly 15 may include a distal end portion 24 configured to engage an inner surface of the converging or frusto-conical section such that the obturator assembly 15 is releaseably securable thereto.
Cannulae 12 are illustrated in
In
Ablation device 100 includes an electrode array “E” and a handle assembly 130. Electrode array “E” may include one or more ablation electrodes 110. In some embodiments, as shown in
In some embodiments, as shown in
As shown in
As shown in
Drug-delivery device 750 includes a housing member 751 and a delivery needle 752 having a distal end 754 and a proximal end 756 coupled to the housing member 751. Housing member 751 defines a chamber 753 therein. In some embodiments, the chamber 753 is configured to contain an agent for delivery through the delivery needle 752 to tissue (not shown).
The pusher rod 960 includes a rod member 961 having a distal end 764, e.g., configured to engage the proximal end 916 of the drug eluting rod 980. In some embodiments, as shown in
A variety of drug agents may be delivered by devices according to embodiments of the present disclosure. Some examples of drug agents which may be delivered by devices according to embodiments of the present disclosure include chemotherapeutic agents such as without limitation cisplatin, paclitaxel, doxorubicin, fluorouracil, as well as other compounds such as without limitation prochlorperzine edisylate, ferrous sulfate, aminocaproic acid, mecamylamine hydrochloride, procainamide hydrochloride, amphetamine sulfate, methamphetamine hydrochloride, benzamphetamine hydrochloride, isoproterenol sulfate, phenmetrazine hydrochloride, bethanechol chloride, methacholine chloride, pilocarpine hydrochloride, atropine sulfate, scopolamine bromide, isopropaniide iodide, tridihexethyl chloride, phenformin hydrochloride, methylphenidate hydrochloride, theophylline cholinate, cephalexin hydrochloride, diphenidol, meclizine hydrochloride, prochlorperazine maleate, phenoxybenzamine, thiethylperzine maleate, anisindone, diphenadione erythrityl tetranitrate, digoxin, isofluorophate, acetazolamide, methazolamide, bendroflumethiazide, chloropromaide, tolazamide, chlormadinone acetate, phenaglycodol, allopurinol, aluminum aspirin, methotrexate, acetyl sulfisoxazole, erythromycin, hydrocortisone, hydrocorticosterone acetate, cortisone acetate, dexamethasone and its derivatives such as betamethasone, triamcinolone, methyltestosterone, 17-S-estradiol, ethinyl estradiol, ethinyl estradiol 3-methyl ether, prednisolone, 17-oc-hydroxyprogesterone acetate, 19-nor-progesterone, norgestrel, norethindrone, norethisterone, norethiederone, progesterone, norgesterone, norethynodrel, aspirin, indornethacin, naproxen, fenoprofen, sulindac, indoprofen, nitroglycerin, isosorbide dinitrate, propranolol, timolol, atenolol, aiprenolol, cimetidine, clonidine, imipramine, levodopa, chlorpromazine, methyldopa, dihydroxyphenylalanine, theophylline, calcium gluconate, ketoprofen, ibuprofen, cephalexin, erythromycin, haloperidol, zomepirac, ferrous lactate, vincamine, diazepam, phenoxybenzamine, diltiazem, mitrinone, capropril, mandol, quanbenz, hydrochlorothiazide, ranitidine, flurbiprofen, fenufen, fluprofen, tolmetin, alciofenac, mefenamic, flufenamic, difiuinal, nimodipine, nitrendipine, nisoldipine, nicardipine, felodipine, lidoflazine, tiapamil, gallopamul, amlodipine, mioflazine, lisinoipril, enalapril, enalaprilat, captopril, ramipril, famotidine, nizatidine, sucralfate, etintidine, tetratolol, minoxidil, chlordazepoxide, diazepam, amitriptyline, and imipramine; opioids such as meperidine, hydrocodone, oxycodone, and semi-synthetic opioids such as oxymorphone, hydromorphone, opiates such as morphine and codeine, opioid antagonists such as without limitation naltrexone, nalbuphine, naloxone as well as opioid agonist/antagonist compounds such as buprenorphine, and synthetic analgesics such as methadone, tramadol, fentanyl and sufentanil.
Some other examples of drug agents which may be delivered by devices according to embodiments of the present disclosure include vitamin and supplements such as vitamins B-12 (cyanocobalamin) and D2, anti-virals such as without limitation acyclorvir and zidovudine; proteins and peptides such as without limitation insulin, colchicine, glucagon, thyroid stimulating hormone, parathyroid and pituitary hormones, calcitonin, renin, prolactin, corticotrdphin, thyrotropic hormone, follicle stimulating hormone, chorionic gonadotropin, gonadotropin releasing hormone, bovine somatotropin, porcine somatotropin, oxytocin, vasopressin, GRE, prolactin, somatostatin, lypressin, pancreozymin, luteinizing hormone, LHRH, LHRH agonists and antagonists, leuprolide, interferons, interleukins, growth hormones such as human growth hormone, bovine growth hormone and porcine growth hormone, fertility inhibitors such as the prostaglandins, fertility promoters, growth factors, coagulation factors, human pancreas hormone releasing factor, analogs and derivatives of these compounds, and pharmaceutically acceptable salts of these compounds, or their analogs or derivatives. On the molecular level, the various forms of the beneficial agent may include uncharged molecules, molecular complexes, and pharmaceutically acceptable acid addition and base addition salts such as hydrochlorides, hydrobromides, acetate, sulfate, laurylate, oleate, and salicylate. Examples of acidic compounds which may be delivered by devices according to embodiments of the present disclosure include salts of metals, amines or organic cations. Derivatives such as esters, ethers and amides may also be used.
A drug agent for delivery by devices according to embodiments of the present disclosure may be used alone or mixed with other agents. A drug agent for delivery by the presently-disclosed devices may include pharmaceutically acceptable excipients, polymeric carriers and/or additional ingredients, such as antioxidants, stabilizing agents, permeation enhancers, polysaccharides, proteins, nucleotides like aptamers, and fatty acids, etc., and fabricated into different forms, such as solution, suspension, gel, colloidal dispersion like liposome, or micro- and nano-particles for controlled delivery of the drug agent. A drug agent for delivery by the presently-disclosed devices may include a thermo-sensitive metal depositor or any such compound that increases the sensitivity of the target tissue, e.g., tumor, to ablation.
A drug agent for delivery by the presently-disclosed devices may include a cryoablation agent, e.g., liquid nitrogen, and may prove complementary to thermal ablation that uses electrosurgical energy at RF or microwave frequencies.
Although embodiments have been described in detail with reference to the accompanying drawings for the purpose of illustration and description, it is to be understood that the inventive processes and apparatus are not to be construed as limited thereby. It will be apparent to those of ordinary skill in the art that various modifications to the foregoing embodiments may be made without departing from the scope of the disclosure.
Number | Name | Date | Kind |
---|---|---|---|
D223367 | Kountz | Apr 1972 | S |
D263020 | Rau, III | Feb 1982 | S |
D266842 | Villers et al. | Nov 1982 | S |
4430081 | Timmermans | Feb 1984 | A |
D278306 | McIntosh | Apr 1985 | S |
D295893 | Sharkany et al. | May 1988 | S |
D295894 | Sharkany et al. | May 1988 | S |
5041098 | Loiterman | Aug 1991 | A |
5356381 | Ensminger | Oct 1994 | A |
D354218 | Van de Peer | Jan 1995 | S |
5403311 | Abele et al. | Apr 1995 | A |
5472441 | Edwards et al. | Dec 1995 | A |
5921982 | Lesh et al. | Jul 1999 | A |
6016452 | Kasevich | Jan 2000 | A |
D424693 | Pruter | May 2000 | S |
D424694 | Tetzlaff et al. | May 2000 | S |
D425201 | Tetzlaff et al. | May 2000 | S |
6176856 | Jandak et al. | Jan 2001 | B1 |
D449886 | Tetzlaff et al. | Oct 2001 | S |
D457958 | Dycus et al. | May 2002 | S |
D457959 | Tetzlaff et al. | May 2002 | S |
6402742 | Blewett et al. | Jun 2002 | B1 |
6477426 | Fenn et al. | Nov 2002 | B1 |
6478793 | Cosman et al. | Nov 2002 | B1 |
6673070 | Edwards et al. | Jan 2004 | B2 |
D487039 | Webster et al. | Feb 2004 | S |
6788977 | Fenn et al. | Sep 2004 | B2 |
D496997 | Dycus et al. | Oct 2004 | S |
D499181 | Dycus et al. | Nov 2004 | S |
7025765 | Balbierz et al. | Apr 2006 | B2 |
D525361 | Hushka | Jul 2006 | S |
D531311 | Guerra et al. | Oct 2006 | S |
D533942 | Kerr et al. | Dec 2006 | S |
D535027 | James et al. | Jan 2007 | S |
7160296 | Pearson | Jan 2007 | B2 |
D541418 | Schechter et al. | Apr 2007 | S |
D541938 | Kerr et al | May 2007 | S |
D564662 | Moses et al. | Mar 2008 | S |
7393352 | Berube | Jul 2008 | B2 |
D576932 | Strehler | Sep 2008 | S |
D594736 | Esjunin | Jun 2009 | S |
D594737 | Kelly et al. | Jun 2009 | S |
D606203 | Husheer et al. | Dec 2009 | S |
D613412 | DeCarlo | Apr 2010 | S |
7842076 | Zikorus et al. | Nov 2010 | B2 |
D634010 | DeCarlo | Mar 2011 | S |
7918852 | Tullis et al. | Apr 2011 | B2 |
8172757 | Jaffe et al. | May 2012 | B2 |
D681810 | DeCarlo | May 2013 | S |
20020120260 | Morris et al. | Aug 2002 | A1 |
20040030250 | Stewart | Feb 2004 | A1 |
20040267256 | Garabedian et al. | Dec 2004 | A1 |
20060041243 | Nayak et al. | Feb 2006 | A1 |
20060241576 | Diederich et al. | Oct 2006 | A1 |
20070073248 | Moenning | Mar 2007 | A1 |
20070161958 | Glenn | Jul 2007 | A1 |
20070244529 | Choi et al. | Oct 2007 | A1 |
20070270710 | Frass et al. | Nov 2007 | A1 |
20070270789 | Berger | Nov 2007 | A1 |
20070287996 | Rioux | Dec 2007 | A1 |
20090149850 | Turovskiy et al. | Jun 2009 | A1 |
20100056989 | McKay | Mar 2010 | A1 |
20100125269 | Emmons et al. | May 2010 | A1 |
20110077644 | Pham et al. | Mar 2011 | A1 |
20130085487 | Temelli et al. | Apr 2013 | A1 |
Number | Date | Country |
---|---|---|
1103807 | Jun 1995 | CN |
390937 | Mar 1924 | DE |
1099658 | Feb 1961 | DE |
1139927 | Nov 1962 | DE |
1149832 | Jun 1963 | DE |
1439302 | Jan 1969 | DE |
2439587 | Feb 1975 | DE |
2455174 | May 1975 | DE |
2407559 | Aug 1975 | DE |
2415263 | Oct 1975 | DE |
2429021 | Jan 1976 | DE |
2460481 | Jun 1976 | DE |
2602517 | Jul 1976 | DE |
2504280 | Aug 1976 | DE |
2627679 | Jan 1977 | DE |
2540968 | Mar 1977 | DE |
2820908 | Nov 1978 | DE |
2803275 | Aug 1979 | DE |
2823291 | Nov 1979 | DE |
2946728 | May 1981 | DE |
3143421 | May 1982 | DE |
3045996 | Jul 1982 | DE |
3120102 | Dec 1982 | DE |
3510586 | Oct 1986 | DE |
3604823 | Aug 1987 | DE |
8712328 | Feb 1988 | DE |
3711511 | Jun 1988 | DE |
3904558 | Aug 1990 | DE |
3942998 | Jul 1991 | DE |
4238263 | May 1993 | DE |
04303882 | Feb 1995 | DE |
4339049 | May 1995 | DE |
29616210 | Nov 1996 | DE |
19608716 | Apr 1997 | DE |
19751106 | May 1998 | DE |
19717411 | Nov 1998 | DE |
19751108 | May 1999 | DE |
19801173 | Jul 1999 | DE |
19848540 | May 2000 | DE |
10217281 | Oct 2003 | DE |
10224154 | Dec 2003 | DE |
10310765 | Sep 2004 | DE |
10328514 | Mar 2005 | DE |
102004022206 | Dec 2005 | DE |
202005015147 | Feb 2006 | DE |
102009015699 | May 2010 | DE |
0 246 350 | Nov 1987 | EP |
0 521 264 | Jan 1993 | EP |
0 556 705 | Aug 1993 | EP |
0 558 429 | Sep 1993 | EP |
0 648 515 | Apr 1995 | EP |
0 836 868 | Apr 1998 | EP |
0 882 955 | Dec 1998 | EP |
1 159 926 | Dec 2001 | EP |
179 607 | Nov 1906 | FR |
1 275 415 | Nov 1961 | FR |
1 347 865 | Jan 1964 | FR |
2 235 669 | Jan 1975 | FR |
2 276 027 | Jan 1976 | FR |
2 313 708 | Dec 1976 | FR |
2 502 935 | Oct 1982 | FR |
2 517 953 | Jun 1983 | FR |
2 573 301 | May 1986 | FR |
2 862 813 | May 2005 | FR |
2 864 439 | Jul 2005 | FR |
5-5106 | Jan 1993 | JP |
05-40112 | Feb 1993 | JP |
06343644 | Dec 1994 | JP |
07265328 | Oct 1995 | JP |
08056955 | Mar 1996 | JP |
08252263 | Oct 1996 | JP |
09000492 | Jan 1997 | JP |
09010223 | Jan 1997 | JP |
11244298 | Sep 1999 | JP |
2000342599 | Dec 2000 | JP |
2000350732 | Dec 2000 | JP |
2001003776 | Jan 2001 | JP |
2001008944 | Jan 2001 | JP |
2001029356 | Feb 2001 | JP |
2001037775 | Feb 2001 | JP |
2001128990 | May 2001 | JP |
2001231870 | Aug 2001 | JP |
2008142467 | Jun 2008 | JP |
20070093068 | Sep 2007 | KR |
20100014406 | Feb 2010 | KR |
20120055063 | May 2012 | KR |
166452 | Nov 1964 | SU |
401367 | Oct 1973 | SU |
727201 | Apr 1980 | SU |
9522285 | Aug 1995 | WO |
9904710 | Feb 1999 | WO |
WO0012010 | Mar 2000 | WO |
0036985 | Jun 2000 | WO |
0108573 | Feb 2001 | WO |
WO0174252 | Oct 2001 | WO |
WO2006105121 | Oct 2006 | WO |
WO2006138719 | Dec 2006 | WO |
WO2008144341 | Nov 2008 | WO |
WO2009065058 | May 2009 | WO |
2010035831 | Apr 2010 | WO |
Entry |
---|
U.S. Appl. No. 13/419,981, filed Mar. 14, 2012, Joseph D. Brannan. |
U.S. Appl. No. 13/430,810, filed Mar. 27, 2012, Joseph D. Brannan. |
U.S. Appl. No. 13/440,690, filed Apr. 5, 2012, Joseph D. Brannan. |
U.S. Appl. No. 13/460,440, filed Apr. 30, 2012, Arnold V. DeCarlo. |
U.S. Appl. No. 13/464,021, filed May 4, 2012, Joseph D. Brannan. |
U.S. Appl. No. 13/477,260, filed May 22, 2012, William R. Reid, Jr. |
U.S. Appl. No. 13/477,320, filed May 22, 2012, Joseph D. Brannan. |
U.S. Appl. No. 13/711,086, filed Dec. 11, 2012, Brannan. |
U.S. Appl. No. 13/835,183, filed Mar. 15, 2013, Arts. |
U.S. Appl. No. 13/835,513, filed Mar. 15, 2013, Brannan. |
U.S. Appl. No. 13/836,014, filed Mar. 15, 2013, Arts. |
U.S. Appl. No. 13/836,353, filed Mar. 15, 2013, Arts. |
U.S. Appl. No. 13/839,562, filed Mar. 15, 2013, Zheng. |
U.S. Appl. No. 13/867,834, filed Jul. 22, 2013, Brannan. |
U.S. Appl. No. 13/871,142, filed Apr. 26, 2013, Ohri. |
U.S. Appl. No. 13/886,080, filed May 2, 2013, Bahney. |
U.S. Appl. No. 13/889,989, filed May 8, 2013, Lee. |
U.S. Appl. No. 13/903,668, filed May 28, 2013, Podhajsky. |
U.S. Appl. No. 13/904,478, filed May 29, 2013, Ohri. |
U.S. Appl. No. 13/908,463, filed Jun. 3, 2013, Brannan. |
U.S. Appl. No. 13/908,555, filed Jun. 3, 2013, Dunning. |
U.S. Appl. No. 13/920,367, filed Jun. 18, 2013, Sharonov. |
U.S. Appl. No. 13/920,411, filed Jun. 18, 2013, Sharonov. |
U.S. Appl. No. 13/922,006, filed Jun. 19, 2013, Nau. |
U.S. Appl. No. 13/942,833, filed Jul. 16, 2013, Sharonov. |
U.S. Appl. No. 13/942,864, filed Jul. 16, 2013, Sharonov. |
U.S. Appl. No. 13/943,452, filed Jul. 16, 2013, Behnke. |
U.S. Appl. No. 13/945,519, filed Jul. 18, 2013, Prakash. |
U.S. Appl. No. 13/945,718, filed Jul. 18, 2013, Rossetto. |
U.S. Appl. No. 13/957,087, filed Aug. 1, 2013, Brannan. |
U.S. Appl. No. 13/973,543, filed Aug. 22, 2013, Orszulak. |
U.S. Appl. No. 14/011,414, filed Aug. 27, 2013, Ohri. |
U.S. Appl. No. 14/011,438, filed Aug. 27, 2013, Ohri. |
U.S. Appl. No. 14/014,937, filed Aug. 30, 2013, Willyard. |
U.S. Appl. No. 14/017,995, filed Sep. 4, 2013, Brannan. |
U.S. Appl. No. 14/018,081, filed Sep. 4, 2013, Brannan. |
European Search Report dated Sep. 26, 2013 for EP 13 17 0016. |
U.S. Appl. No. 08/136,098, filed Oct. 14, 1993; Roger A. Stern. |
U.S. Appl. No. 08/483,742, filed Jun. 7, 1995; Roger A. Stern. |
Alexander et al., “Magnetic Resonance Image-Directed Stereotactic Neurosurgery: Use of Image Fusion with Computerized Tomography to Enhance Spatial Accuracy” Journal Neurosurgery, 83 (1995), pp. 271-276. |
Anderson et al., “A Numerical Study of Rapid Heating for High Temperature Radio Frequency Hyperthermia” International Journal of Bio-Medical Computing, 35 (1994), pp. 297-307. |
Anonymous. (1999) Auto Suture MIBB Site Marker: Single Use Clip Applier, United States Surgical (Product instructions), 2 pages. |
Anonymous. (2001) Disposable Chiba Biopsy Needles and Trays, Biopsy and Special Purpose Needles Cook Diagnostic and Interventional Products Catalog (products list), 4 pages. |
Anonymous. (1987) Homer Mammalok™ Breast Lesion Needle/Wire Localizer, Namic® Angiographic Systems Division, Glens Falls, New York, (Hospital products price list), 4 pages. |
Anonymous. (1999) MIBB Site Marker, United States Surgical (Sales brochure), 4 pages. |
Anonymous. Blunt Tubes with Finished Ends. Pointed Cannula, Popper & Sons Biomedical Instrument Division, (Products Price List), one page, Jul. 19, 2000. |
Anonymous. Ground Cannulae, ISPG, New Milford, CT, (Advertisement) one page, Jul. 19, 2000. |
B. Levy M.D. et al., “Randomized Trial of Suture Versus Electrosurgical Bipolar Vessel Sealing in Vaginal Hysterectomy” Obstetrics & Gynecology, vol. 102, No. 1, Jul. 2003. |
B. Levy M.D. et al., “Update on Hysterectomy New Technologies and Techniques” OBG Management, Feb. 2003. |
B. Levy M.D., “Use of a New Vessel Ligation Device During Vaginal Hysterectomy” FIGO 2000, Washington, D.C. |
B. F. Mullan et al., (May 1999) “Lung Nodules: Improved Wire for CT-Guided Localization,” Radiology 211:561-565. |
B. T. Heniford M.D. et al., “Initial Research and Clinical Results with an Electrothermal Bipolar Vessel Sealer” Oct. 1999. |
Bergdahl et al., “Studies on Coagulation and the Development of an Automatic Computerized Bipolar Coagulator” Journal of Neurosurgery 75:1 (Jul. 1991), pp. 148-151. |
Bulletin of the American Physical Society, vol. 47, No. 5, Aug. 2002, p. 41. |
C. F. Gottlieb et al., “Interstitial Microwave Hyperthermia Applicators having Submillimetre Diameters”, Int. J. Hyperthermia, vol. 6, No. 3, pp. 707-714, 1990. |
C. H. Durney et al., “Antennas for Medical Applications”, Antenna Handbook: Theory Application and Design, p. 24-40, Van Nostrand Reinhold, 1988 New York, V.T. Lo, S.W. Lee. |
Carbonell et al., “Comparison of the Gyrus PlasmaKinetic Sealer and the Valleylab LigaSure.TM. Device in the Hemostasis of Small, Medium, and Large-Sized Arteries” Carolinas Laparoscopic and Advanced Surgery Program, Carolinas Medical Center,Charlotte, NC 2003. |
Carus et al., “Initial Experience With the LigaSure.TM. Vessel Sealing System in Abdominal Surgery” Innovations That Work, Jun. 2002. |
Chicharo et al., “A Sliding Goertzel Algorithm” Aug. 1996 DOS pp. 283-297 Signal Processing, Elsevier Science Publishers B.V. Amsterdam, NL, vol. 52, No. 3. |
Chou, C.K., (1995) “Radiofrequency Hyperthermia in Cancer Therapy,” Chapter 941n Biologic Effects of Nonionizing Electromagnetic Fields, CRC Press, Inc., pp. 1424-1428. |
Chung et al., “Clinical Experience of Sutureless Closed Hemorrhoidectomy with LigaSureTM” Diseases of the Colon & Rectum, vol. 46, No. 1, Jan. 2003. |
Cosman et al., “Methods of Making Nervous System Lesions” in William RH, Rengachary SS (eds): Neurosurgery, New York: McGraw-Hill, vol. 111, (1984), pp. 2490-2499. |
Cosman et al., “Radiofrequency Lesion Generation and its Effect on Tissue Impedence”, Applied Neurophysiology, 51:230-242, 1988. |
Cosman et al., “Theoretical Aspects of Radiofrequency Lesions in the Dorsal Root Entry Zone” Neurosurgery 15: (1984), pp. 945-950. |
Crawford et al., “Use of the LigaSure.TM. Vessel Sealing System in Urologic Cancer Surger” Grand Rounds in Urology 1999, vol. 1, Issue 4, pp. 10-17. |
Dulemba et al., “Use of a Bipolar Electrothermal Vessel Sealer in Laparoscopically Assisted Vaginal Hysterectomy” Sales/Product Literature; Jan. 2004. |
E. David Crawford, “Evaluation of a New Vessel Sealing Device in Urologic Cancer Surgery” Sales/Product Literature 2000. |
E. David Crawford, “Use of a Novel Vessel Sealing Technology in Management of the Dorsal Veinous Complex” Sales/Product Literature 2000. |
Esterline, “Light Key Projection Keyboard” Advanced Input Systems, located at: <http://www.advanced-input.com/lightkey> 2002. |
Esterline Product Literature, “Light Key: Visualize a Virtual Keyboard. One With No Moving Parts”, Nov. 1, 2003; 4 pages. |
Geddes et al., “The Measurement of Physiologic Events by Electrical Impedence” Am. J. MI, Jan. Mar. 1964, pp. 16-27. |
Goldberg et al., “Image-guided Radiofrequency Tumor Ablation: Challenges and Opportunities—Part I”, (2001) J Vasc. Interv. Radiol, vol. 12, pp. 1021-1032. |
Goldberg et al. (1995) “Saline-enhanced RF Ablation: Demonstration of Efficacy and Optimization of Parameters”, Radiology, 197(P): 140 (Abstr). |
Goldberg et al., “Tissue Ablation with Radiofrequency: Effect of Probe Size, Gauge, Duration, and Temperature on Lesion Volume” Acad Radio (1995) vol. 2, No. 5, pp. 399-404. |
H. Schwarzmaier et al., “Magnetic Resonance Imaging of Microwave Induced Tissue Heating” Dept. of Laser Medicine & Dept. of Diagnostic Radiology; Heinrich-Heine-University, Duesseldorf, Germany; Dec. 8, 1994; pp. 729-731. |
Heniford et al., “Initial Results with an Electrothermal Bipolar Vessel Sealer” Surgical Endoscopy (2001) 15:799-801. |
Herman at al., “Laparoscopic Intestinal Resection With the LigaSureTM Vessel Sealing System: A Case Report” Innovations That Work, Feb. 2002. |
Humphries Jr. et al., “Finite-Element Codes to Model Electrical Heating and Non-Llnear Thermal Transport in Biological Media”, Proc. ASME HTD-355, 131 (1997). |
Ian D. McRury et al., The Effect of Ablation Sequence and Duration on Lesion Shape Using Rapidly Pulsed Radiofrequency Energy Through Electrodes, Feb. 2000, Springer Netherlands, vol. 4; No. 1, pp. 307-320. |
Jarrett et al., “Use of the LigaSureTM Vessel Sealing System for Peri-Hilar Vessels in Laparoscopic Nephrectomy” Sales/Product Literature 2000. |
Johnson et al., “Evaluation of a Bipolar Electrothermal Vessel Sealing Device in Hemorrhoidectomy” Sales/Product Literature, Jan. 2004. |
Johnson, “Evaluation of the LigaSureTM Vessel Sealing System in Hemorrhoidectormy” American College of Surgeons (ACS) Clinic La Congress Poster (2000). |
Johnson et al., “New Low-Profile Applicators for Local Heating of Tissues”, IEEE Transactions on Biomedical Engineering, vol. BME-31, No. 1, Jan. 1984, pp. 28-37. |
Johnson, “Use of the LigaSureTM Vessel Sealing System in Bloodless Hemorrhoidectomy” Innovations That Work, Mar. 2000. |
Joseph G. Andriole M.D. et al., “Biopsy Needle Characteristics Assessed in the Laboratory”, Radiology 148: 659-662, Sep. 1983. |
Joseph Ortenberg, “LigaSureTM System Used in Laparoscopic 1st and 2nd Stage Orchiopexy” Innovations That Work, Nov. 2002. |
Kennedy et al., “High-burst-strength, feedback-controlled bipolar vessel sealing” Surgical Endoscopy (1998) 12: 876-878. |
Kopans, D.B. et al., (Nov. 1985) “Spring Hookwire Breast Lesion Localizer: Use with Rigid-Compression. Mammographic Systems,” Radiology 157(2):537-538. |
Koyle et al., “Laparoscopic Palomo Varicocele Ligation in Children and Adolescents” Pediatric Endosurgery & Innovative Techniques, vol. 6, No. 1, 2002 |
LigaSureTM Vessel Sealing System, the Seal of Confidence in General , Gynecologic, Urologic, and Laparaoscopic Surgery, Sales/Product Literature, Jan. 2004. |
Livraghi et al., (1995) “Saline-enhanced RF Tissue Ablation in the Treatment of Liver Metastases”, Radiology, p. 140 (Abstr). |
Lyndon B. Johnson Space Center, Houston, Texas, “Compact Directional Microwave Antenna for Localized Heating,” NASA Tech Briefs, Mar. 2008. |
M. A. Astrahan, “A Localized Current Field Hyperthermia System for Use with 192-Iridium Interstitial Implants” Medical Physics. 9(3), May/Jun. 1982. |
Magdy F. Iskander et al., “Design Optimization of Interstitial Antennas”, IEEE Transactions on Biomedical Engineering, vol. 36, No. 2, Feb. 1989, pp. 238-246. |
McGahan et al., (1995) “Percutaneous Ultrasound-guided Radiofrequency Electrocautery Ablation of Prostate Tissue in Dogs”, Acad Radiol, vol. 2, No. 1: pp. 61-65. |
McLellan et al., “Vessel Sealing for Hemostasis During Pelvic Surgery” Int'l Federation of Gynecology and Obstetrics FIGO World Congress 2000, Washington, DC. |
MDTECH product literature (Dec. 1999) “FlexStrand”: product description, 1 page. |
MDTECH product literature (Mar. 2000) I'D Wire: product description, 1 page. |
Medtrex Brochure “The O.R. Pro 300” 1 page, Sep. 1998. |
Michael Choti, “Abdominoperineal Resection with the LigaSureTM Vessel Sealing System and LigaSureTM Atlas 20 cm Open Instrument” Innovations That Work, Jun. 2003. |
Muller et al., “Extended Left Hemicolectomy Using the LigaSureTM Vessel Sealing System” Innovations That Work. LJ, Sep. 1999. |
Murakami, R. et al., (1995). “Treatment of Hepatocellular Carcinoma: Value of Percutaneous Microwave Coagulation,” American Journal of Radiology (AJR) 164:1159-1164. |
Ni Wei et al., “A Signal Processing Method for the Coriolis Mass Flowmeter Based on a Normalized . . . ” Journal of Applied Sciences—Yingyong Kexue Xuebao, Shangha CN, vol. 23, No. 2:(Mar. 2005); pp. 160-184. |
Ogden, “Goertzel Alternative to the Fourier Transform” Jun. 1993 pp. 485-487 Electronics World; Reed Business Publishing, Sutton, Surrey, BG, vol. 99, No. 9, 1687. |
Olsson M.D. et al., “Radical Cystectomy in Females” Current Surgical Techniques in Urology, vol. 14, Issue 3, 2001. |
Organ, L W., “Electrophysiologic Principles of Radiofrequency Lesion Making” Appl. Neurophysiol, vol. 39: pp. 69-76 (1976/77). |
P. R. Stauffer et al., “Interstitial Heating Technologies”, Thermoradiotheray and Thermochemotherapy (1995) vol. I, Biology, Physiology, Physics, pp. 279-320. |
Palazzo et al., “Randomized clinical trial of LigaSureTM versus open haemorrhoidectomy” British Journal of Surgery 2002,89,154-157 “Innovations in Electrosurgery” Sales/Product Literature; Dec. 31, 2000. |
Paul G. Horgan, “A Novel Technique for Parenchymal Division During Hepatectomy” The American Journal of Surgery, vol. 181, No. 3, Apr. 2001, pp. 236-237. |
Peterson et al., “Comparison of Healing Process Following Ligation with Sutures and Bipolar Vessel Sealing” Surgical Technology International (2001). |
R. Gennari et al., (Jun. 2000) “Use of Technetium-99m-Labeled Colloid Albumin for Preoperative and Intraoperative Localization of Non palpable Breast Lesions,” American College of Surgeons. 190(6):692-699. |
Valleylab Brochure, “Reducing Needlestick Injuries in the Operating Room” 1 page, Mar. 2001. |
Reidenbach, (1995) “First Experimental Results with Special Applicators for High-Frequency Interstitial Thermotherapy”, Society Minimally Invasive Therapy, 4(Suppl 1):40 (Abstr). |
Richard Wolf Medical Instruments Corp. Brochure, “Kleppinger Bipolar Forceps & Bipolar Generator” 3 pages, Jan. 1989. |
Rothenberg et al., “Use of the LigaSureTM Vessel Sealing System in Minimally Invasive Surgery in Children” Int'l Pediatric Endosurgery Group (I PEG) 2000. |
Sayfan et al., “Sutureless Closed Hemorrhoidectomy: A New Technique” Annals of Surgery, vol. 234, No. 1, Jul. 2001, pp. 21-24. |
Sengupta et al., “Use of a Computer-Controlled Bipolar Diathermy System in Radical Prostatectomies and Other Open Urological Surgery” ANZ Journal of Surgery (2001) 71.9 pp. 538-540. |
Sigel et al., “The Mechanism of Blood Vessel Closure by High Frequency Electrocoagulation” Surgery Gynecology & Obstetrics, Oct. 1965 pp. 823-831. |
Solbiati et al., (2001) “Percutaneous Radio-frequency Ablation of Hepatic Metastases from Colorectal Cancer: Longterm Results in 117 Patients”, Radiology, vol. 221, pp. 159-166. |
Solbiati et al. (1995) “Percutaneous US-guided RF Tissue Ablation of Liver Metastases: Long-term Follow-up”, Radiology, pp. 195-203. |
Stagegaard, N., Petersen H.H., Chen X., Svendsen J.H., “Indication of the Radiofrequency Induced Lesion Size by Pre-ablation Measurements” Europace (2005) 7, 525-534. |
Strasberg et al., “Use of a Bipolar Vassel-Sealing Device for Parenchymal Transection During Liver Surgery” Journal of Gastrointestinal Surgery, vol. 6, No. 4, Jul./Aug. 2002 pp. 569-574. |
Sugita et al., “Bipolar Coagulator with Automatic Thermocontrol” J. Neurosurg., vol. 41, Dec. 1944, pp. 777-779. |
Sylvain Labonte et al., “Monopole Antennas for Microwave Catheter Ablation”, IEEE Trans. on Microwave Theory and Techniques, vol. 44, No. 10, pp. 1832-1840, Oct. 1995. |
T. Matsukawa et al., “Percutaneous Microwave Coagulation Therapy in Liver Tumors”, Acta Radiologica, vol. 38, pp. 410-415, 1997. |
T. Seki et al., (1994) “Ultrasonically Guided Percutaneous Microwave Coagulation Therapy for Small Hepatocellular Carcinoma,” Cancer 74(3):817-825. |
Urologix, Inc.—Medical Professionals: TargisTM Technology (Date Unknown). “Overcoming the Challenge” located at: <http://www.urologix.comlmedicaUtechnology.html > Nov. 18, 1999; 3 pages. |
Urrutia et al., (1988). “Retractable-Barb Needle for Breast Lesion Localization: Use in 60 Cases,” Radiology 169 (3):845-847. |
Valleylab Brochure, “Valleylab Electroshield Monitoring System” 2 pages, Nov. 1995. |
ValleyLab Brochure, “Electosurgery: A Historical Overview”, Innovations in Electrosurgery, 1999. |
Vallfors et al., “Automatically Controlled Bipolar Electrocoagulation—‘COA-COMP’” Neurosurgical Review 7:2-3 (1984) pp. 187-190. |
W. Scott Helton, “LigaSureTM Vessel Sealing System: Revolutionary Hemostasis Product for General Surgery” Sales/ Product Literature 1999. |
Wald et al., “Accidental Burns”, JAMA, Aug. 16, 1971, vol. 217, No. 7, pp. 916-921. |
Walt Boyles, “Instrumentation Reference Book”, 2002, Butterworth-Heinemann, pp. 262-264. |
Wonnell et al., “Evaluation of Microwave and Radio Frequency Catheter Ablation in a Myocardium-Equivalent Phantom Model”, IEEE Transactions on Biomedical Engineering, vol. 39, No. 10, Oct. 1992; pp. 1086-1095. |
European Search Report for EP 14173860 dated Mar. 9, 2015. |
Number | Date | Country | |
---|---|---|---|
20150065964 A1 | Mar 2015 | US |